Dias Daniela, Esteves Susana, Andrade Sónia, Maciel Joana, Cavaco Daniela, Simões-Pereira Joana, Pereira Maria Conceição
Endocrinology Department, Portuguese Cancer Institute of Lisbon, Lisbon, Portugal.
Clinical Research Department, Portuguese Cancer Institute of Lisbon, Lisbon, Portugal.
Case Rep Oncol. 2020 Mar 31;13(1):347-357. doi: 10.1159/000506395. eCollection 2020 Jan-Apr.
There is a great controversy about hormonal replacement therapy in women among the members of the scientific community. Cancer survivors have sometimes had their ovary function totally or partially destroyed, thus affecting their development and quality of life. In this study, we were looking for adverse effects caused, eventually, by estroprogestative therapy in a cohort of supplemented survivors. The occurrence of breast cancer was our main concern. Ours is a retrospective study based on the clinical records of 174 survivors of several cancer diseases. Their median ages within each of the following time frames were: diagnosis - 22 years old; start of endocrine treatment - 26 years old, and duration of treatment - 12 years old. Evaluation was composed of breast cancer assessment, osteopenia and osteoporosis incidence, and vascular events. We have found a very low incidence of breast cancer as well as of vascular events. After treatment, a high percentage of our sample displayed bone mass improvement.
科学界成员对于女性激素替代疗法存在很大争议。癌症幸存者的卵巢功能有时会完全或部分遭到破坏，从而影响其发育和生活质量。在本研究中，我们探寻雌激素 - 孕激素疗法最终在一组接受补充治疗的幸存者中所引发的不良反应。乳腺癌的发生是我们主要关注的问题。我们的研究是一项基于174名多种癌症疾病幸存者临床记录的回顾性研究。他们在以下每个时间框架内的年龄中位数分别为：确诊时——22岁；开始内分泌治疗时——26岁，以及治疗时长——12岁。评估内容包括乳腺癌评估、骨质减少和骨质疏松发病率以及血管事件。我们发现乳腺癌以及血管事件的发生率非常低。治疗后，我们样本中的很大一部分显示骨量有所改善。
